INHIBITOR OF MAP KINASE INTERACTING SERINE/THREONINE KINASE 1 (MNK1) AND MAP KINASE INTERACTING SERINE/THREONINE KINASE 2 (MNK2), CANCER THERAPY AND THERAPEUTIC COMBINATIONS

The present invention describes 4,6-diphenyl-1H-pyrazolo[3,4-b]pyridin-3-amine (EB1), or a pharmaceutically acceptable salt thereof, as a selective MNK inhibitor for use in the treatment of cancers of an hormone-dependent organs, including triple-negative breast cancer, prostate cancer and other ref...

Full description

Saved in:
Bibliographic Details
Main Authors TEIXIDÓ CLOSA, Jordi, BORRELL BILBAO, José Ignacio, SUAREZ CABRERA, Leticia, BOU PETIT, Elisabeth, PEG CAMARA, Vicente, MOROTE ROBLES, Joan, HÜMMER, Stefan, ESTRADA TEJEDOR, Roger, GUIJARRO CARRILLO, Pedro Jesus, MARTINEZ SÁEZ, Elena, RAMON Y CAJAL AGÜERAS, Santiago, SANTAMARIA MARGALEF, Anna, CASTELLVI VIVES, Josep
Format Patent
LanguageEnglish
French
German
Published 18.05.2022
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention describes 4,6-diphenyl-1H-pyrazolo[3,4-b]pyridin-3-amine (EB1), or a pharmaceutically acceptable salt thereof, as a selective MNK inhibitor for use in the treatment of cancers of an hormone-dependent organs, including triple-negative breast cancer, prostate cancer and other referable cancers with p-eIF4E overexpression due to increased MNK activity. The invention also includes particular therapeutic combinations including the 4,6-diphenyl-1H-pyrazolo[3,4-b]pyridin-3-amine.
Bibliography:Application Number: EP20200739952